A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 1, 2008, Pages 19-24

  Hroch, M ^a   Chladek, J ^a   Simkova, M ^b   Vaneckova, J ^b   Grim, J ^b   Martinkova, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Erythrocytes; Methotrexate; Pharmacokinetics; Psoriasis

Indexed keywords

ALANINE AMINOTRANSFERASE; HOMOCYSTEINE; METHOTREXATE; POLYGLUTAMIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ERYTHROCYTE; FEMALE; GEOMETRY; HEMATOLOGY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MEAN CORPUSCULAR VOLUME; MORNING DOSAGE; PILOT STUDY; PRIORITY JOURNAL; PSORIASIS VULGARIS; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; AGED; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; ERYTHROCYTES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 37749040774     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02264.x     Document Type: Article

References (17)

1. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006; 54: 1366-1377.
2. Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 2004; 50: 301-309.
3. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: An assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615.
4. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol 2000; 14: 382-388.
5. Chladek J, Grim J, Martinkova J et. al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 2002; 54: 147-156.
6. Chladek J, Grim J, Martinkova J, Simkova M, Vaneckova J. Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis. Basic Clin Pharmacol Toxicol 2005; 96: 247-248.
7. Dervieux T, Orentas Lein D, Marcelletti J et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003; 49: 1632-1641.
8. Dervieux T, Furst D, Lein DO et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: Results of a multicentred cross sectional observational study. Ann Rheum Dis 2005; 64: 1180-1185.
9. Schroder H, Fogh K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1988; 21: 145-149.
10. Da Costa M, Iqbal MP. The transport and accumulation of methotrexate in human erythrocytes. Cancer 1981; 48: 2427-2432.
11. Chladek J, Martinkova J, Simkova M, Vaneckova J, Koudelkova V, Nozickova M. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 1998; 53: 437-444.
12. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006; 33: 1442-1446.
13. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665.
14. Weinstein GD, Frost P. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971; 103: 33-38.
15. Jacobs SA, Adamson RH, Chabner BA, Derr CJ, Johns DC. Stoichiometric inhibition of mammalian dihydrofolate reductase by the gamma-glutamyl metabolite of methotrexate, 4-amino-4-deoxy-N-10-methylpteroylglutamyl-gamma-glutamate. Biochem Biophys Res Commun 1975; 63: 692-698.
16. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985; 260: 9720-9726.
17. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985; 82: 4881-4885.